Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,127.74 -11.52 -0.37%
FTSE 100 6,583.61 -0.56 -0.01%
DAX 9,302.02 -15.80 -0.17%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Pfizer (PFE) Stock Offer, Spinoff Report Sees Fundamental Break-Up Post Zoetis (ZTS); Remember Bristol Myers & Mead Johnson?



  Pfizer (PFE) Stock Offer, Spinoff Report Sees Fundamental Break-Up Post
  Zoetis (ZTS); Remember Bristol Myers & Mead Johnson?

Business Wire

NEW YORK & LONDON -- June 19, 2013

400m shares are due to hit the market and today’s the last day for tendering
Pfizer (PFE) common shares in exchange for Zoetis (ZTS) stock. Further, with
over 20% upside seen in the next year for both PFE and ZTS, an even bigger
catalyst awaits smart investors in terms of a larger restructuring Spinoff
from PFE in the coming years, according to UK independent and top proven
research advisor on global special situations and break-ups, TSR (The Spinoff
Report® / www.spinoffreport.com).

TSR claim they’ve discovered the hidden fundamental catalysts and have equally
added each to their client Model Portfolio holdings. These have notably
outperformed the S&P500 by over 6x in 66 months.

For TSR’s latest 32 page research, you can request it by clicking here.

Speaking to Ryan Mendy of TSR, he comments, “Under the strong leadership of
CEO, Ian Read (appointed in 2010 plus got his stock awards compensation
tripled in 2011), PFE’s strategic desire to restructure its business portfolio
has enhanced shareholder returns via the selloff of its nutrition business to
Nestle SA for $12bn and now the separation of ZTS.”

“Returning +106% in 5 years, PFE offers an attractive mix to investors of 1)
inexpensive and discounted valuations, 2) a solid dividend and cash flow yield
with limited earnings risk, 3) incentivized management, and 4) similar to
Abbott Laboratories and its Spinoff, AbbVie (ABBV), the opportunity from the
potential Spinoff of its innovative and value core businesses in 2016, which
our research finds can unlock significant value for shareholders”, Mendy
continued.

Discounted Opportunity?

PFE is offering shareholders a discount of 7% to the ZTS share price. For full
analysis of the exchange offer, the potential selling/volatility and upside,
click here

Similar Exchange Offer: Bristol Myers Squibb (BMY)...

Similar to the current PFE/ZTS exchange offer, Bristol Myers Squibb (BMY) had
Split-off its 83% stake in the baby formula maker Mead Johnson (MJN) in
November 2009, following an IPO of its 17% stake earlier in February 2009.
Post IPO, MJN shares delivered a stunning return of 148% over the next twenty
months.

Akin to PFE’s exchange offer, BMY shareholders were able to exchange their
shares for MJN shares, though at a slightly higher discount of 10%.

Contact:

The Spinoff Report®
Ryan Mendy
rm@spinoffreport.com
+1-(212)-714-7046
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement